D.E. Shaw & Co’s Sionna Therapeutics SION Stock Holding History

D.E. Shaw & Co’s Portfolio SION Stock Details SION Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,742	Closed	-$236K	–	5179
2025 Q4	$236K	Buy	+5,742	New	+$218K	﹤0.01%	4264

Other funds holding SION

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co's SION Position: Q1 2026 in Review

D.E. Shaw & Co sold out of Sionna Therapeutics (SION) in Q1 2026, closing a stake of 5,742 shares — an estimated $236K sold.

D.E. Shaw & Co first reported a position in SION in Q4 2025 and held it in 1 quarter. The position peaked at $236K in Q4 2025. 122 funds tracked by Wall St. Rank hold SION as of Q1 2026.

D.E. Shaw & Co reported no remaining Sionna Therapeutics position as of Q1 2026 after selling out during the quarter.
D.E. Shaw & Co sold 5,742 Sionna Therapeutics shares in Q1 2026, an estimated $236K.
D.E. Shaw & Co first reported a position in Sionna Therapeutics in Q4 2025 and held it in 1 quarter.
D.E. Shaw & Co's Sionna Therapeutics position peaked at $236K in Q4 2025.
122 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.